STOCK TITAN

[Form 4] ELITE PHARMACEUTICALS INC /NV/ Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.

The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.

Elite Pharmaceuticals (ELTP) ha presentato un modulo 4 (Form 4) annunciando che l'EVP Operations Douglas Plassche ha venduto azioni ordinarie. Il 10/02/2025, ha eseguito una vendita (codice S) di 800.000 azioni al prezzo di $0,624 per azione. Dopo la transazione, possiede beneficialmente 3.500.000 azioni, detenute direttamente.

La segnalazione identifica la persona responsabile come dirigente (EVP Operations) e indica che la forma di proprietà è diretta. Nessuna operazione su strumenti derivati è stata riportata in Tabella II.

Elite Pharmaceuticals (ELTP) presentó un Formulario 4 divulgando que el EVP Operations, Douglas Plassche, vendió acciones comunes. El 02/10/2025, ejecutó una venta (código S) de 800,000 acciones a un precio de $0.624 por acción. Después de la transacción, posee beneficiariamente 3,500,000 acciones, mantenidas directamente.

La presentación identifica a la persona informante como un cargo (EVP Operations) e indica que la forma de propiedad es directa. No se reportaron transacciones de valores derivados en la Tabla II.

Elite Pharmaceuticals (ELTP)는 Form 4를 제출했고 EVP Operations의 Douglas Plassche가 일반 주식을 매도했다고 공시했습니다. 2025년 10월 2일, 그는 800,000주$0.624의 가격으로 매도하는 거래(S 코드)를 실행했습니다. 거래 후 그는 직접 보유하고 있는 3,500,000주를 보유합니다.

공시는 보고자(직책: EVP Operations)를 경영진으로 식별하고 소유 형태를 직접(direct)으로 표시합니다. 표 II에는 파생증권 거래가 보고되지 않았습니다.

Elite Pharmaceuticals (ELTP) a déposé un Form 4 révélant que le cadre supérieur EVP Operations, Douglas Plassche, a vendu des actions ordinaires. Le 02/10/2025, il a exécuté une vente (code S) de 800 000 actions au prix de $0,624 par action. Suite à la transaction, il détiendra bénéficiairement 3 500 000 actions, détenues directement.

Le dossier identifie la personne déclarée comme un dirigeant (EVP Operations) et indique que la forme de propriété est directe. Aucune transaction sur valeurs dérivées n'a été rapportée dans le Tableau II.

Elite Pharmaceuticals (ELTP) hat ein Form 4 eingereicht und bekannt gegeben, dass EVP Operations Douglas Plassche Stammaktien verkauft hat. Am 02.10.2025 führte er einen Verkauf (Code S) von 800.000 Aktien zu einem Preis von $0,624 pro Aktie durch. Nach der Transaktion besitzt er direkt 3.500.000 Aktien, die er beneficiell hält.

Die Einreichung identifiziert die meldende Person als Offizier (EVP Operations) und weist darauf hin, dass die Eigentumsform direkt ist. In Tabelle II wurden keine Derivate-Geschäfte gemeldet.

Elite Pharmaceuticals (ELTP) قد قدمت نموذج 4 يعلن أن مسؤول العمليات التنفيذي EVP Operations، Douglas Plassche، باع أسهم عادية. في 02/10/2025، نفذ بيعاً (رمز S) لـ 800,000 سهم بسعر $0.624 للسهم. بعد الصفقة، يمتلك بنسبة فاعلة 3,500,000 سهم، مُلك مباشرة.

يحدد الملف الشخص المبلغ عنه كموظف (EVP Operations) ويشير إلى أن شكل الملكية مباشر. لم تُبلغ أي معاملات أوراق مالية مشتقة في الجدول II.

Elite Pharmaceuticals (ELTP) 提交了 Form 4,披露 EVP Operations 的 Douglas Plassche 出售普通股。于 2025/10/02,他执行了一个股票卖出交易(代码 S),卖出 800,000 股,每股价格为 $0.624。交易后,他直接持有 3,500,000 股,为受益所有。

该申报将报告人识别为高管(EVP Operations),并指明所有权形式为直接所有。在表 II 中未报告任何衍生证券交易。

Positive
  • None.
Negative
  • None.

Elite Pharmaceuticals (ELTP) ha presentato un modulo 4 (Form 4) annunciando che l'EVP Operations Douglas Plassche ha venduto azioni ordinarie. Il 10/02/2025, ha eseguito una vendita (codice S) di 800.000 azioni al prezzo di $0,624 per azione. Dopo la transazione, possiede beneficialmente 3.500.000 azioni, detenute direttamente.

La segnalazione identifica la persona responsabile come dirigente (EVP Operations) e indica che la forma di proprietà è diretta. Nessuna operazione su strumenti derivati è stata riportata in Tabella II.

Elite Pharmaceuticals (ELTP) presentó un Formulario 4 divulgando que el EVP Operations, Douglas Plassche, vendió acciones comunes. El 02/10/2025, ejecutó una venta (código S) de 800,000 acciones a un precio de $0.624 por acción. Después de la transacción, posee beneficiariamente 3,500,000 acciones, mantenidas directamente.

La presentación identifica a la persona informante como un cargo (EVP Operations) e indica que la forma de propiedad es directa. No se reportaron transacciones de valores derivados en la Tabla II.

Elite Pharmaceuticals (ELTP)는 Form 4를 제출했고 EVP Operations의 Douglas Plassche가 일반 주식을 매도했다고 공시했습니다. 2025년 10월 2일, 그는 800,000주$0.624의 가격으로 매도하는 거래(S 코드)를 실행했습니다. 거래 후 그는 직접 보유하고 있는 3,500,000주를 보유합니다.

공시는 보고자(직책: EVP Operations)를 경영진으로 식별하고 소유 형태를 직접(direct)으로 표시합니다. 표 II에는 파생증권 거래가 보고되지 않았습니다.

Elite Pharmaceuticals (ELTP) a déposé un Form 4 révélant que le cadre supérieur EVP Operations, Douglas Plassche, a vendu des actions ordinaires. Le 02/10/2025, il a exécuté une vente (code S) de 800 000 actions au prix de $0,624 par action. Suite à la transaction, il détiendra bénéficiairement 3 500 000 actions, détenues directement.

Le dossier identifie la personne déclarée comme un dirigeant (EVP Operations) et indique que la forme de propriété est directe. Aucune transaction sur valeurs dérivées n'a été rapportée dans le Tableau II.

Elite Pharmaceuticals (ELTP) hat ein Form 4 eingereicht und bekannt gegeben, dass EVP Operations Douglas Plassche Stammaktien verkauft hat. Am 02.10.2025 führte er einen Verkauf (Code S) von 800.000 Aktien zu einem Preis von $0,624 pro Aktie durch. Nach der Transaktion besitzt er direkt 3.500.000 Aktien, die er beneficiell hält.

Die Einreichung identifiziert die meldende Person als Offizier (EVP Operations) und weist darauf hin, dass die Eigentumsform direkt ist. In Tabelle II wurden keine Derivate-Geschäfte gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Plassche Douglas

(Last) (First) (Middle)
165 LUDLOW AVE.

(Street)
NORTHVALE, NJ 07647

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELITE PHARMACEUTICALS INC /NV/ [ ELTP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP Operations
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
common stock 10/02/2025 S 800,000 D $0.624 3,500,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Douglas Plassche 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ELTP report on Form 4?

An officer sold 800,000 shares of common stock at $0.624 on 10/02/2025.

Who is the reporting person in ELTP's Form 4 and what is their role?

Douglas Plassche, EVP Operations.

How many ELTP shares does the insider own after the transaction?

The insider beneficially owns 3,500,000 shares directly after the sale.

What was the transaction code in the ELTP Form 4?

Transaction code S, indicating an open market or private sale.

Were any derivative securities reported in ELTP's Form 4?

No derivative securities were reported in Table II.

What is the ownership form for the reported ELTP shares?

Ownership form is Direct (D).
Elite Pharmaceuticals Inc

OTC:ELTP

ELTP Rankings

ELTP Latest News

ELTP Stock Data

738.96M
835.91M
21.95%
2.16%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Northvale